MedTrace Logo

An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers

NCT03553992 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2020-10-19

No results posted yet for this study

Summary

The 2-year research plan will test the Extended Put It Out Project (POP-6) in a pilot randomized trial (N=168) compared to TSP-6, as well as comparing POP-6 and TSP-6 to the POP-3 and TSP-3 interventions from a previously-conducted trial. Participants will be young adults who smoke, identify as sexual or gender minorities (SGM), and use Facebook. Primary outcome will be biochemically verified 7-day abstinence from smoking at 3 and 6 months. Secondary outcomes will be a quit attempt (y/n), stage of change, and thoughts about tobacco abstinence at 3 and 6 months.

Conditions

  • Tobacco Use
  • Smoking
  • Tobacco Dependence
  • Tobacco Use Disorder
  • Tobacco Use Cessation
  • Tobacco Smoking
  • Smoking Cessation
  • Smoking, Cigarette
  • Smoking, Tobacco

Interventions

BEHAVIORAL

POP-6:

90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults Drug: nicotine patch 14-day supply of nicotine patch

BEHAVIORAL

TSP-6:

90 days of Facebook messaging, weekly live sessions targeting tobacco use Drug: nicotine patch 14-day supply of nicotine patch

Sponsors & Collaborators

Principal Investigators

  • Gary L. Humfleet, PhD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-29
Primary Completion
2019-07-07
Completion
2019-07-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553992 on ClinicalTrials.gov